PMID- 37092466
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230426
IS  - 2411-5150 (Electronic)
IS  - 2411-5150 (Linking)
VI  - 7
IP  - 2
DP  - 2023 Apr 4
TI  - The Most-Cited Articles on Retinoblastoma: A Fifty-Year Perspective.
LID - 10.3390/vision7020033 [doi]
LID - 33
AB  - PURPOSE: To summarize the characteristics and trends of interest in 
      retinoblastoma (Rb) in the last 50 years. METHODS: The Web of Science Database 
      was used to find all studies focused on Rb published from 1970 to 2018. The term 
      "retinoblastoma" was used to search for the 100 most cited records. RESULTS: The 
      mean number of citations was 153.55 +/- 88.9. The majority were from the United 
      States (US) (n = 68). Drs. Shields authored 38% of the papers. The number of 
      citations per year was positively correlated with the number of authors, r = 0.26 
      (p = 0.008). The number of patients was significantly associated with the number 
      of citations per year (p = 0.012). Although papers on radiotherapy were the most 
      common, publications about intra-arterial chemotherapy (IAC) were associated with 
      88.3% more citations per year (p = 0.031) and papers on intravenous chemotherapy 
      (IVC) were associated with 40.3% more citations per year (p= 0.04). Review and 
      meta-analysis studies had a higher median of citations (10.5) than interventional 
      (6.4) or observational (5.2) studies. CONCLUSIONS: This study compiles a 
      comprehensive analysis of the most-cited articles on Rb. Studies with a higher 
      number of citations per year were associated with IAC, which emphasizes the 
      significance of the advances in Rb treatments that allow for the saving of eyes 
      and vision as well as lives. Review studies had more citations than observational 
      or interventional studies. More citations were associated with a larger number of 
      authors or more reported patients per paper. These findings highlight the 
      importance of collaborations to achieve relevant, high-quality research of Rb.
FAU - Shemesh, Rachel
AU  - Shemesh R
AUID- ORCID: 0000-0001-9572-4623
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
AD  - Sheba Medical Center, Goldschleger Eye Institute, Tel-Hashomer, Ramat Gan 52621, 
      Israel.
FAU - Sandler, Hunter
AU  - Sandler H
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
FAU - Dichter, Sarah
AU  - Dichter S
AD  - Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of 
      Technology, Haifa 3200003, Israel.
FAU - Fabian, Ido Didi
AU  - Fabian ID
AUID- ORCID: 0000-0002-0846-5131
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
AD  - Sheba Medical Center, Goldschleger Eye Institute, Tel-Hashomer, Ramat Gan 52621, 
      Israel.
FAU - Mezer, Eedy
AU  - Mezer E
AUID- ORCID: 0000-0002-2818-7538
AD  - Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of 
      Technology, Haifa 3200003, Israel.
AD  - Department of Ophthalmology, Rambam Health Care Campus, Haifa 3109601, Israel.
FAU - Wygnanski-Jaffe, Tamara
AU  - Wygnanski-Jaffe T
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
AD  - Sheba Medical Center, Goldschleger Eye Institute, Tel-Hashomer, Ramat Gan 52621, 
      Israel.
LA  - eng
PT  - Journal Article
DEP - 20230404
PL  - Switzerland
TA  - Vision (Basel)
JT  - Vision (Basel, Switzerland)
JID - 101733282
PMC - PMC10123740
OTO - NOTNLM
OT  - bibliometrics
OT  - chemotherapy
OT  - citations
OT  - retinoblastoma
OT  - treatment
COIS- The authors declare no conflict of interest.
EDAT- 2023/04/24 06:41
MHDA- 2023/04/24 06:42
PMCR- 2023/04/04
CRDT- 2023/04/24 05:53
PHST- 2023/02/03 00:00 [received]
PHST- 2023/02/26 00:00 [revised]
PHST- 2023/03/30 00:00 [accepted]
PHST- 2023/04/24 06:42 [medline]
PHST- 2023/04/24 06:41 [pubmed]
PHST- 2023/04/24 05:53 [entrez]
PHST- 2023/04/04 00:00 [pmc-release]
AID - vision7020033 [pii]
AID - vision-07-00033 [pii]
AID - 10.3390/vision7020033 [doi]
PST - epublish
SO  - Vision (Basel). 2023 Apr 4;7(2):33. doi: 10.3390/vision7020033.